The purpose is to investigate the association between treatment with empagliflozin and other available SGLT2 inhibitors and cardiovascular events in patients with type 2 diabetes in Finland. In the study, empagliflozin and other available SGLT2 inhibitors will be compared with DPP-4 inhibitors, which represent an alternative to SGLT2 inhibitors.
Changes to the permit: extension of validity
Issuer of the original permit: Kela
